Production (Stage)
Nektar Therapeutics
NKTR
$0.666
-$0.0088-1.30%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -38.26% | 117.26% | 19.15% | -2.43% | 73.14% |
| Total Depreciation and Amortization | -73.49% | -79.90% | -41.42% | -32.64% | -30.19% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 125.67% | -2,317.91% | -270.54% | -64.68% | -107.08% |
| Change in Net Operating Assets | 97.81% | -136.35% | 133.83% | 215.42% | -169.16% |
| Cash from Operations | -2.43% | 1.83% | -4.30% | 26.82% | 7.76% |
| Capital Expenditure | 98.73% | -93.67% | -1,918.18% | -14.81% | 63.74% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 125.04% | -126.75% | -15.25% | -32.23% | -52.68% |
| Cash from Investing | 126.86% | 246.40% | -18.25% | -32.53% | -52.56% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 133.33% | 591.67% | -- | 5.56% | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -99.98% | 591.67% | -- | 5.56% | -- |
| Foreign Exchange rate Adjustments | 87.50% | 312.50% | 71.43% | -100.93% | -117.78% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -140.09% | 147.71% | -84.72% | 21.07% | 218.57% |